There is a large amount of cell death during cytotoxic cancer therapy such as radiation therapy 1,2 . It is normally assumed that dying or dead cells get absorbed by scavenger cells such as macrophages or other surviving cells in the vicinity. The small number of surviving tumor cells, if any, would presumably gradually and slowly prolif erate and reestablish the tumor. However, studies that originated more than 40 years ago 3,4 have indicated that tumors respond to radiotherapy by initiating a process called accelerated repopula tion. In this process, the few surviving cells that escaped death after exposure to radiotherapy or chemotherapy can rapidly repopulate the badly damaged tumor by proliferating at a markedly acceler ated pace. This phenomenon, for which little is understood at the molecular level, has played a major part in modern radiotherapy and chemotherapy 5 .
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Investigators have made many efforts to understand the mole cular mechanism of tumor repopulation after cytotoxic therapy. For example, one study found that radiationinduced upregulation of angiogenesis in tumors was linked with activation of upstream trans criptional factors such as hypoxiainducible factor1 (ref. 6 ). Other recent studies have also indicated the involvement of macrophages in facilitating tumor recovery after radiation 7, 8 . Furthermore, one group implicated the integrity of endothelial cells in tumor response to radiotherapy 9 . These reports, although revealing key mechanisms of tumor regrowth, have fallen short of describing the initial driving events responsible for tumor repopulation after radiotherapy.
In this study, we examined the hypothesis that dying cells in the tumor mass may provide the initial signals to promote tumor repopu lation. Specifically, we hypothesized that dying cells could release growthpromoting signals to stimulate the proliferation of surviving cells. Our data show a crucial role for intratumoral dying cells in promoting the rapid repopulation of tumors from a small number of live tumor cells. In addition, we made the unexpected discovery that caspase 3, a cysteine protease involved in the 'execution' phase of cellular apoptosis, is a key regulator of growthpromoting signals generated from the dying cells. We believe this newly discovered caspasemediated tumor repopulation mechanism has key roles in cytotoxic cancer therapy.
RESULTS

Tumor cell repopulation stimulated by cell death in vitro
To test our hypothesis, we carried out experiments to examine whether dying tumor cells could stimulate the growth of living tumor cells. To simulate in vivo scenarios where the vast majority of tumor cells are killed by radiation or chemotherapy, we seeded a small number (about 500) of firefly luciferase (Fluc)labeled mouse breast cancer 4T1 cells onto a bed of a much larger number (2.5 × 10 5 ) of unlabeled
In cancer treatment, apoptosis is a well-recognized cell death mechanism through which cytotoxic agents kill tumor cells. Here we report that dying tumor cells use the apoptotic process to generate potent growth-stimulating signals to stimulate the repopulation of tumors undergoing radiotherapy. Furthermore, activated caspase 3, a key executioner in apoptosis, is involved in the growth stimulation. One downstream effector that caspase 3 regulates is prostaglandin E 2 (PGE 2 ), which can potently stimulate growth of surviving tumor cells. Deficiency of caspase 3 either in tumor cells or in tumor stroma caused substantial tumor sensitivity to radiotherapy in xenograft or mouse tumors. In human subjects with cancer, higher amounts of activated caspase 3 in tumor tissues are correlated with markedly increased rate of recurrence and death. We propose the existence of a cell death-induced tumor repopulation pathway in which caspase 3 has a major role.
'feeder' 4T1 tumor cells that had been irradi ated with Xrays at various doses. Growth of the small number of labeled living cells was then monitored through noninvasive bio luminescence imaging 10 (see Supplementary  Fig. 1 for data validating the biolumines cence quantification of tumor cells). Our results indicated that 4T1Fluc cells grew significantly faster when seeded onto dying cells than when seeded alone (Fig. 1a) . In addition, there was a dose dependent response from the feeder cells, with nonirradiated feeder cells showing no supportive role and those irradiated with higher radiation doses showing a higher growthenhancing ability (Fig. 1a) . Additional supporting evidence came from combinations of other dying versus living cell types, which also showed growthstimulating properties of dying cells (Supplementary Figs. 2 and 3) .
Because in solid tumors stromal cells are involved in modulating tumor growth, we also evaluated whether dying fibroblast cells could promote tumor cell growth. Lethally irradiated mouse embryonic fibroblast cells stimulated the growth of various Fluclabeled tumor cells significantly in vitro (Fig. 1b) .
Tumor cell repopulation stimulated by cell death in vivo
We next examined whether cell death-stimulated tumor cell prolifera tion could be observed in vivo. We injected a mix of untreated, Fluc labeled and lethally irradiated, unlabeled tumor cells (at a ratio of 1:250, or 1,000 live 4T1Fluc cells mixed with 2.5 × 10 5 unlabeled, lethally irradiated 4T1 cells) subcutaneously into the hind legs of nude mice. Subsequently, we followed the growth of the Fluclabeled tumor cells over time noninvasively through bioluminescence imaging. As controls, we injected an equal number of Fluclabeled 4T1 tumor cells mixed with live, unlabeled 4T1 tumor cells into the contralateral hind legs. The presence of lethally irradiated tumor cells markedly increased the growth of Fluclabeled tumor cells when compared with Fluclabeled tumor cells injected together with live tumor cells (Fig. 1c) . In fact the difference in cell numbers, which were derived by dividing total biolu minescent signals by signal intensity of individual cells ( Supplementary  Fig. 1 ), between the two groups grew exponentially larger and reached as great as 700fold by the end of the experiment (Fig. 1c) .
We observed similar in vivo tumor growth-promoting proper ties for mouse embryonic fibroblast (MEF) cells that were irradiated (Fig. 1d) . Fluclabeled 4T1 cells coinjected with irradiated fibroblast cells grew to signal intensities 400fold higher than those from 4T1Fluc cells injected alone in contralateral hind legs.
Caspase 3 regulates tumor cell repopulation in vitro
What is the molecular mechanism for the observed cell death-stimulated proliferation of surviving cells? We reasoned that among the many cellular processes activated or deactivated in dying cells, the fac tors and processes directly responsible for cell death are most likely to be involved in regulating the growthpromoting properties of dying cells. Therefore, we hypothesized that caspases, the proteases that are involved in both the initiation and the execution of pro grammed cell death 11 , might be involved in regulating the growth promoting properties of dying cells. To examine this hypothesis, we obtained MEF cells with genetic deletion of the Casp3 gene 12, 13 , which encodes the main executioner caspase in mammalian cells, and evaluated the ability of these cells to support the growth of a small number of Fluclabeled tumor cells. Deficiency in Casp3 significantly compromised the ability of lethally irradiated MEF cells to stimulate the growth of Fluclabeled mouse (4T1) and human (MDAMB231 and HCT116) tumor cells (Fig. 2a) . The proliferation of Fluclabeled tumor cells among the irradiated Casp3deficient (Casp3 −/− ) cells reached a degree similar to Fluclabeled tumor cells seeded alone (Fig. 2a) , suggesting that caspase 3 was largely respon sible for growth stimulation by dying cells.
We confirmed the role of caspase 3 in lethally irradiated 4T1 cells through shRNAmediated knockdown of Casp3 expression in feeder cells (Fig. 2b) We also confirmed its involvement in the human breast The Supplementary Note contains additional information on these data. To examine whether the proteolytic activity of caspase 3 is required for its role in tumor repopulation, we transduced a dominantnegative version of caspase 3 (C163A) 14 to inhibit caspase 3 cleavage activity in 4T1 cells. 4T1 cells transduced with a gene encoding dominantnegative caspase 3 (C163A) 14 completely lost their ability to support the growth of 4T1Fluc cells (Fig. 2c) . We obtained similar results by use of a chemical inhibitor of caspase 3, zVADfmk ( Supplementary Fig. 9 ).
To confirm that caspase 3 was activated in irradiated cells, we car ried out comprehensive immunoblot analyses of various proteins in the apoptotic pathway in irradiated 4T1 ( Fig. 2d Fig. 10 ) cells. Caspases 3 and 9 and the downstream cytochrome c were activated in both 4T1 and MEF cells in a dosedependent manner, whereas caspase 8 was not activated.
Caspase 3 regulation of tumor cell repopulation in vivo
To examine the importance of caspase 3 in cell death-stimulated tumor repopulation in vivo, we mixed lethally irradiated wildtype or caspase 3-knockout MEF cells with a small number (500) of Fluclabeled 4T1 cells and injected them subcutaneously into nude mice. In contrast to the potent stimulation of 4T1Fluc tumor cellular growth by lethally irradiated wildtype MEF cells, lethally irradiated caspase 3-deficient MEF cells induced significantly attenuated growth stimulation (Fig. 2e) . The difference between the two groups was as great as 1,000fold at later stages of observation (Fig. 2e) . In fact, in separate experiments, 4T1Fluc cells injected together with lethally irradiated caspase 3-deficient MEF cells grew at a similar rate to 4T1Fluc cells injected alone in the contralateral legs, indicating a lack of growth stimulation from Casp3 −/− cells (Supplementary Fig. 11 ).
We also confirmed the role of caspase 3 in regulating growthpro moting properties of dying cells in vivo by coinjecting 4T1Fluc cells with lethally irradiated 4T1 cells transduced with an shRNA mini gene targeted against caspase 3. We observed a significant reduction in the ability of lethally irradiated 4T1 cells to stimulate the growth of 4T1Fluc cells (Fig. 2f) , consistent with the results obtained with Casp3 −/− MEF cells.
Growth of injected tumor cells in established tumors
To show that caspase 3 is indeed activated in solid tumors during radiotherapy, we established mouse 4T1 tumor cells transduced with a caspase 3 reporter. Our caspase 3 reporter consists of a luciferase GFP protein further fused with a polyubiquitin domain (with the whole reporter under the control of a constitutively active cytomegalo virus promoter) that makes the fusion protein susceptible to rapid, proteasomebased degradation. A caspase 3 cleavage site inserted between the polyubitquitin domain and the luciferaseGFP domain ensures that the reporter is stabilized and detectable when caspase 3 is activated (Fig. 3a, left) . Supplementary Figure 12 shows data sup porting the functionality of our caspase 3 reporter. We established tumors from reportercontaining cells and irradiated them with Xrays (6 Gy) when they reached 5-7 mm in diameter. We then observed caspase 3 activation in the tumors through quantitative bioluminescence imaging. Our results showed that caspase 3 was significantly activated (as much as 30fold at its peak when compared with that of nonirradiated control tumors) at days 3, 5 and 7 after radiotherapy (Fig. 3a) . In another experiment, we injected a small number of Fluclabeled 4T1 tumor cells (about 1,000) into previously nonirradiated and irradiated 4T1 tumors established from unlabeled cells in the left and rights sides of host mice, respectively. We then observed the growth of labeled tumor cells through bioluminescence imaging. Cells injected into irradiated tumors grew at a significantly faster rate than those injected into nontreated tumors (Fig. 3b) , consistent with earlier results.
In a further experiment, we injected 4T1 cells stably transduced with GFP into irradiated tumors and allowed them to grow for 5-8 d. We then killed the mice, excised the tumors and examined them for expression of various proteins. There was a clear relationship between activated caspase 3 and the proliferation of injected, GFPlabeled tumor cells in irradiated tumor cells, as indicated by the complementary patterns of caspase 3 staining and injected tumor cell staining (Fig. 3c) . In contrast, we observed very little injected tumor cell growth and caspase activation in nonirradiated tumors (Fig. 3c) . In addition to caspase activation, irradiated tumors also showed increased, localized neovasculature, as determined by SMA staining (Fig. 3c) .
Irradiated tumors also showed a significant influx of macrophages (Supplementary Fig. 13) , which have been shown to stimulate tumor angiogenesis and tumor growth.
A downstream target for caspase 3 in tumor repopulation
We next attempted to identify the downstream factors of caspase 3 that were involved in generating growthpromoting factors from the dying cells. We focused on cytosolic calciumindependent phospholipase A 2 , group 6 (iPLA 2 , encoded by PLA2G6), because it had previously been reported that its phosopholipase activity was activated by caspase 3 cleavage [15] [16] [17] . Earlier reports have shown that caspase 3mediated iPLA 2 (Pla2g6) activation led to increased production of arachidonic acid 15 , whose downstream eicosanoid derivatives (such as PGE 2 ) had been implicated in stimulating tumor growth 18 and stem cell proliferation 19 . To evaluate the potential involvement of the caspase activated iPLA 2 -arachidonic acid-PGE 2 axis in cell death-induced tumor cell proliferation, we transduced shRNA targeting Pla2g6 into 4T1 tumor cells or wildtype MEF cells and examined whether these cells, when lethally irradiated, could support Fluclabeled tumor cell growth to the same extent as their wildtype untreated coun terparts. In both MEF and 4T1 cells, expression of shRNA against Pla2g6 significantly reduced the ability of these cells to stimulate Fluclabeled 4T1 cellular proliferation after irradiation (Fig. 4a) . Western blot analysis also indicated that iPLA 2 is indeed activated in a caspase 3-dependent manner ( Supplementary Fig. 14) in both 4T1 and MEF cells. These results are consistent with multiple earlier reports [15] [16] [17] . We next transduced a truncated version of the Pla2g6 gene (∆Pla2g6), which encodes an iPLA 2 fragment (containing the catalytic domain) that is a predicted product of caspase 3 cleavage of iPLA 2 , into caspase 3-deficient MEF cells. After ∆Pla2g6 transduction (inset of Fig. 4a) , lethally irradiated Casp3 −/− cells were significantly better at stimulating the growth of Fluclabeled 4T1Fluc cells both in vitro (Fig. 4a) and in vivo (Fig. 4b and Supplementary Fig. 15 ) when compared with parental Casp3 −/− cells.
Knocking down Pla2g6 gene expression (Fig. 4c) significantly reduced the ability of lethally irradiated MEF cells to stimulate the growth of 4T1Fluc cells in vivo (Fig. 4c and Supplementary  Fig. 16 ). In established wildtype or Pla2g6 knockdown 4T1 tumors, growth of subsequently transplanted 4T1Fluc cells was significantly slowed (Supplementary Fig. 17 ).
Caspase 3, iPLA 2 activation and PGE 2 release Because arachidonic acid is one of two main catalytic products of acti vated iPLA 2 (the other being lysophosphatidic choline), we measured radiationinduced release of arachidonic acid into the extracellular milieu to examine the potential relationship between caspase 3 and arachidonic acid release. We found that irradiation of wild type MEF cells stimulated the release of arachidonic acid into the supernatant (Fig. 5a) . However, this release was substantially reduced in Casp3 −/− MEF cells, indicating a crucial role for caspase 3. In addition, ara chidonic acid release was also markedly reduced in 4T1 cells with knockdown of Casp3 gene expression (Fig. 5a) .
Because PGE 2 , a key regulator of tumor growth, is a downstream product of arachidonic acid, we measured PGE 2 production induced by ionizing radiation in the supernatants of cells. Exposure to ionizing radiation markedly induced the production of PGE 2 in wildtype MEF cells as well as in 4T1 tumor cells when compared with nonirradiated cells (Fig. 5b) . However, in Casp3 −/− MEF cells and in 4T1shCasp3 cells, the production of PGE 2 in irradiated cells was considerably reduced compared with wildtype cells (Fig. 5b) . In contrast, trans duction of a constitutively active, truncated Pla2g6 (Fig. 4b, inset) (which encodes a protein that is equivalent to a caspasecleaved version of iPLA 2 ), substantially restored PGE 2 production in Casp3 −/− MEF cells (Fig. 5b) . In an additional experiment, cyclo oxygenase 2 and its upstream transcription factor nuclear factorκB, which have crucial roles in PGE 2 production, were shown to be acti vated in a caspase 3-independent manner (Supplementary Fig. 18 ). Consistent with this, indomethacin (a cyclooxygenase 1 and 2 inhibitor) administration effectively suppressed growth of intratu morally injected 4T1 and HCT116 cells (Supplementary Fig. 19) .
Treatment of a small number (1,000) of tumor cells with PGE 2 gave the treated cells a significant head start, allowing them to grow at a faster pace than untreated cells when injected into mice (Fig. 5c) . In contrast, shRNAmediated downregulation of EP 2 , a receptor for PGE 2 , in 4T1Fluc cells markedly attenuated the proliferation of the latter when seeded together with lethally irradiated 4T1 cells (Supplementary Fig. 20) .
Caspase 3 and radiosensitivities of tumors in mice and man
To examine the prospect of enhancing cancer radiotherapy through inhibition of caspase 3, we carried out two experiments in mouse tumor models. In the first experiment, we used MCF7 cells, which are naturally deficient in caspase 3 expression (Supplementary Fig. 8) . We established tumor xenografts in female nude mice using both parental MCF7 cells and a modified MCF7 cell line with an exog enously transduced copy of the gene encoding human caspase 3 (CASP3). The transduction of CASP3 into MCF7 cells rendered them significantly more susceptible to apoptosis ( Supplementary  Fig. 8) . Unexpectedly, CASP3 transduction also enabled MCF7 cells to form tumors at a faster pace in the absence of radiotherapy. Although we do not fully understand the mechanism for this observa tion, we speculate that cell death is common during tumor growth, and growthpromoting signals from the dying cells may have a role in regulating overall tumor growth even in the absence of cytotoxic treatments (Fig. 6a) . Notably, the presence of caspase 3 made MCF7 CASP3 tumors significantly more resistant to radiotherapy than parental MCF7 tumors, which disappeared completely after two doses of 6 Gy Xrays and did not regrow during the entire course of observation (Fig. 6a) . In contrast, tumors established from MCF7 CASP3 cells kept growing after irradiation despite growing more slowly than control, nonirradiated tumors (Fig. 6a) . Because MCF7 CASP3 cells showed substantially more and faster radiationinduced apoptototic cell death in vitro (Supplementary Fig. 8) , our results are consistent with the interpretation that MCF7CASP3 tumors showed more resistance to radiation as a result of faster tumor cell repopulation instead of intrinsic resistance, although we could not rule out additional mechanisms such as enhanced tumor angio genesis due to caspase 3-mediated PGE 2 production.
In the second experiment, we attempted to examine the potential role of stromaderived caspase 3 activities in tumor response to radiotherapy, because stroma accounts for a substantial percent age of tumor mass. We established tumors in wildtype as well as Casp3 −/− mice with B16F10 cells, which is a metastatic and radio resistant tumor line syngeneic with the C57BL/6 mice. We car ried out radiotherapy (two doses of 8 Gy) when tumors reached 5-7 mm in diameter. B16F10 tumors grown in Casp3 −/− mice showed significant sensitivity to radiotherapy when compared with those in wildtype C57BL/6 mice (Fig. 6b) . Our results therefore confirm the role of caspase 3 in both tumor cells and tumor stroma in stimulating tumor response to radiotherapy.
To determine the relevance of caspasemediated tumor repopula tion in human cancer treatment, we evaluated caspase 3 status in two cohorts of human subjects with cancer. In the first cohort, 39 subjects with head and neck cancer treated with radiotherapy or chemoradiotherapy at the Princess Margaret Hospital in Toronto (see Supplementary Table 2 for subject characteristics) were examined for activated caspase 3 through immunohistochemical analysis of pretreat ment tumor biopsies. Consistent with our results in mice (Fig. 6a,b) , subjects with high (>10% staining) amounts of cleaved (and thus activated) caspase 3 in their tumor samples showed a significantly (P = 0.011) higher rate of tumor recurrence ( Fig. 6c and Supplementary  Fig. 21 ). In the second cohort, 48 subjects with advanced stage breast cancer treated at Shanghai No. 1 People's hospital (see Supplementary  Table 3 for subject characteristics) were analyzed for activated caspase 3 expression through immunohistochemical analysis of pretreatment biopsies. Subjects with strong cleaved caspase 3 staining (>10% cells stained) had significantly (P = 0.0002) shorter survival times ( Fig. 6d  and Supplementary Fig. 22) . The mechanism by which caspase 3 is activated in pretreatment biopsies remains unknown. In addition, we analyzed public domain microarray data from a previously published study 20 . In 249 subjects with breast cancer from Sweden and Singapore, elevated caspase 3 mRNA levels correlated with signi ficantly elevated risk (P = 0.0001) of relapse (Supplementary Fig. 23 ). On the basis of our results, we conclude that elevated tumor caspase 3 levels predict worse treatment outcomes in people with cancer.
We propose the existence of a cell deathmediated tumor repopula tion pathway in which caspase 3 plays a major role (Fig. 6e) .
DISCUSSION
In tumors exposed to cytotoxic cancer therapeutics, cells live and die depending on the extent of damage they have suffered. In this study, we have provided evidence that these two types of cells are inextricably associated, manifested by our obser vation that apoptotic tumor cells stimulate the repopulation of tumors from a small number of surviving cells. Caspase 3, the master executioner during apoptotic cell death, serves as a direct link between cell death and tumor repopulation. Despite the paradoxical nature of these results at first glance, however, we believe the observed link between cellular death and proliferation may be one of the key mechanisms of metazoan tissue homeostasis exploited by tumors to preserve themselves when damaged by cytotoxic treat ments. Indeed, the phenomenon of apoptosisstimulated tissue regen eration has been observed by other investigators in lower organisms such as Drosophila and hydra systems [21] [22] [23] . In these cases, it has been proposed that apoptotic cells stimulate socalled compensatory pro liferation for tissue regeneration. The mechanisms involved are not entirely clear. However, it was reported that βcatenin-Wnt signaling was involved in some instances of compensatory proliferation 23 . In this context, it is notable that PGE 2 has been shown to activate the βcatenin-Wnt signaling pathway in colon cancer 18 . Therefore, the caspaseiPLA 2 pathway that we unveiled here may be part of the evolutionarily conserved mechanism for tissue repair. Although a direct role for caspase 3 in stimulating tumor repopu lation has not been described before to our knowledge, there have been many published studies on nonapoptotic roles of caspases in mammalian biology. Examples of these include caspasemediated stimulation of differentiation [24] [25] [26] , dedifferentiation 27 and T cell activation 28 . Other possible caspase 3-mediated effects include how the host immune system will be mobilized against cancer cells, which can be heavily influenced by how cells die (for example, necrosis versus apoptosis).
One of the practical implications of this study is a new and counter intuitive approach to enhancing cancer radiotherapy through caspase 3 inhibition. Our results point to the potential efficacy of adjuvant use of caspase 3 inhibitors in radiotherapy. Another implication of our study is the potential use of activated caspase 3 as a biomarker to predict tumor response to treatment, as supported by data from immunohistochemical analyses of human tumor samples.
Finally, we believe our newly discovered, caspase 3-regulated tumor repopulation pathway has profound implications for the understand ing of cancer biology and treatment. It also provides an example of how tumor cells usurp a key metazoan tissue regeneration mecha nism 29 for their own survival.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
